伊拉斯卡制药

US · ERAS #2103 按市值排名上市于 2021

13.39 -1.48 -9.95%

实时 - 追踪5344个代码 - 心跳于526秒前 · 2026-10-16 20:02

✦ 量化股权信号计算方式说明

减持

最近一期（2026/Q3）披露持股的机构数量增加了2家。
机构持股总比例下降了9.6个百分点。

机构持股

机构持股比例: 81.31% -9.60pp
机构数量: 293 +2
数据截至: 2026/Q3 较上一报告期

持股变动 vs 资金流向

方向分歧

机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Mutual Fund34.36%

Hedge Fund22.29%

VC/PE Fund20.09%

Individual/Insider9.65%

Public Company2.42%

Private Company0.96%

Sovereign Wealth Fund0.61%

Insurance Company0.38%

Government Pension Fund0.19%

Other9.06%

主要股东截至 2026-06-30

Jonathan Lim 9.25% · 32.36M 股

T. Rowe Price Group, Inc. 7.85% · 27.46M 股

Frazier Life Sciences Management, LP 7.14% · 24.98M 股

BlackRock 6.05% · 21.15M 股

RTW Investments, LP 5.13% · 17.95M 股

VR Management, LLC 5.12% · 17.89M 股

Vanguard Capital Management, LLC 3.75% · 13.10M 股

State Street Global Advisors 3.48% · 12.18M 股

Logos Global Management, L.P. 3.47% · 12.15M 股

Artal Group S.A. 3.26% · 11.40M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 38次买入 · 12次卖出

姓名	职务	持股比例
Jonathan Lim	Chairperson & CEO	9.25%
Alexander Casdin	Independent Director	0.19%
David Chacko	CFO & Chief Business Officer	0.08%
James Bristol	Independent Director	0.06%
Pratik Multani	Independent Director	0.05%
Ebun Garner	General Counsel	0.01%
Valerie Harding-Start	Independent Director	0.01%
Julie Hambleton	Independent Director	0.00%
Jean I. Liu	Independent Director	--
Michael Varney	Chairman of Research & Development, Scientific Advisory Board member and Director	--

内部人交易最近的 Form 4 申报记录

日期	姓名	职务	类型	股数	价格
2026-08-09	Charles Fuchs	President of Research & Development	Other Derivative Acquisition	+1,300,000	$18.12
2026-06-25	Jean I. Liu	Independent Director	Other Derivative Acquisition	+29,888	$16.01
2026-06-25	Alexander Casdin	Independent Director	Other Derivative Acquisition	+29,888	$16.01
2026-06-25	Pratik Multani	Independent Director	Other Derivative Acquisition	+29,888	$16.01
2026-06-25	James Bristol	Independent Director	Other Derivative Acquisition	+29,888	$16.01
2026-06-25	Julie Hambleton	Independent Director	Other Derivative Acquisition	+29,888	$16.01
2026-06-25	Valerie Harding-Start	Independent Director	Other Derivative Acquisition	+29,888	$16.01
2026-03-31	Ebun Garner	General Counsel	Derivative Exercise and Sale	-80,000	$1.70–16.40
2026-03-03	Shannon Morris	Chief Medical Officer	Derivative Exercise and Sale	-20,000	$1.70–15.04
2026-01-28	Michael Varney	Chairman of Research & Development, Scientific Advisory Board member and Director	Other Derivative Acquisition	+96,000	$10.31
2026-01-28	Jonathan Lim	Chairperson & CEO	Other Derivative Acquisition	+2,000,000	$10.31
2026-01-28	Ebun Garner	General Counsel	Other Derivative Acquisition	+560,000	$10.31
2026-01-28	Shannon Morris	Chief Medical Officer	Other Derivative Acquisition	+625,000	$10.31
2026-01-28	David Chacko	CFO & Chief Business Officer	Other Derivative Acquisition	+640,000	$10.31
2026-01-06	Ebun Garner	General Counsel	Derivative Exercise and Sale	-120,000	$1.70–5.59
2025-12-31	Jean I. Liu	Independent Director	Other Derivative Acquisition	+20,617	$3.72
2025-12-31	Alexander Casdin	Independent Director	Other Derivative Acquisition	+23,872	$3.72
2025-12-31	Pratik Multani	Independent Director	Other Derivative Acquisition	+19,532	$3.72
2025-12-31	James Bristol	Independent Director	Other Derivative Acquisition	+37,762	$3.72
2025-12-31	Valerie Harding-Start	Independent Director	Other Derivative Acquisition	+24,306	$3.72

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 20:02:15 · 仅供参考，不构成投资建议，也未考虑您的具体情况。